febril
neutropenia
fn
common
danger
consequ
myelosuppress
chemotherapi
occur
part
diseas
process
bacteri
bloodstream
infect
commonli
diagnos
caus
febril
neutropenia
gramposit
organ
frequent
isol
howev
gramneg
organ
becom
preval
worri
trend
toward
resist
organ
fn
prolong
last
day
increas
risk
invas
fungal
infect
prompt
recognit
diagnosi
initi
treatment
broadspectrum
antibiot
essenti
avoid
complic
prevent
rapid
progress
sepsi
possibl
death
short
articl
summaris
definit
caus
pathogenesi
appli
physiolog
manag
fn
children
intern
uniformli
agre
definit
fn
unit
kingdom
uk
nation
institut
health
care
excel
nice
defin
fn
temperatur
c
absolut
neutrophil
count
anc
less
cellsmicrolitr
less
x
l
neutrophil
cutoff
chosen
risk
overwhelm
sepsi
increas
anc
drop
x
l
sever
guidelin
propos
complex
definit
exampl
singl
fever
c
temperatur
c
one
hour
two
episod
fever
c
within
h
period
anc
cutoff
also
vari
x
l
x
l
prolong
fn
neutropenia
coexist
fever
last
five
day
increas
risk
invas
fungal
infect
febril
neutropenia
fn
commonli
encount
context
patient
receiv
myelosuppress
drug
use
treatment
haematolog
solid
tumour
cancer
commonli
encount
complic
childhood
cancer
treatment
mortal
untreat
fn
emerg
antibiot
resist
make
fn
particularli
challeng
mortal
rate
uk
doubl
year
larg
due
emerg
resist
gramneg
organ
absenc
fever
system
unwel
oncolog
patient
preclud
consider
underli
infect
inflammatori
respons
blunt
neutropen
patient
may
present
fever
despit
establish
infect
particular
patient
receiv
highdos
steroid
may
mask
temperatur
due
immun
system
suppress
equal
febril
system
unwel
cancer
patient
normal
anc
also
treat
seriou
infect
possibl
qualit
immunosuppress
particularli
true
children
haematolog
malign
neutrophil
function
impair
even
anc
within
normal
rang
cellular
humor
immun
also
impair
especi
neutropenia
prolong
patholog
fn
multifactori
contributori
factor
includ
pancytopenia
marrow
replac
humor
cellular
immun
qualit
defect
mucos
central
venou
cathet
cvc
infect
pancytopenia
caus
administr
cytotox
drug
direct
malign
invas
bone
marrow
acquir
bone
marrow
failur
anaemia
thrombocytopenia
correct
transfus
neutropenia
particular
pose
signific
danger
patient
neutrophil
form
bodi
major
defenc
infect
particularli
bacteri
fungal
infect
neutrophil
phagocytos
microb
erad
via
sever
method
includ
product
highli
toxic
reactiv
oxygen
speci
ro
pathogencontain
vacuol
fusion
neutrophil
granul
contain
variou
antimicrobi
mediat
vacuol
neutrophil
extracellular
trap
format
neutrophil
also
assist
gener
fever
releas
endogen
pyrogen
respons
infect
absenc
neutrophil
epitheli
cell
releas
cytokin
caus
fever
addit
direct
marrow
invas
underli
malign
also
caus
chemotact
phagocyt
defect
neutrophil
impair
abil
reach
site
infect
contain
especi
true
haematolog
malign
chemotherapyinduc
mucos
caus
breakdown
usual
mucos
barrier
gastrointestin
gi
system
allow
transloc
commens
gi
tract
bacteria
fungi
bloodstream
thought
major
caus
factor
fn
caus
gramneg
organ
cvc
becom
colon
skin
commens
bacteria
lead
invas
infect
organ
poor
cvc
hygien
also
lead
infect
gramneg
organ
polymicrobi
infect
uncommon
major
standard
chemotherapi
regimen
use
manag
childhood
cancer
caus
period
myelosuppress
neutropenia
often
last
seven
day
fn
common
children
receiv
chemotherapi
acut
myeloid
leukaemia
aml
acut
lymphoblast
leukaemia
either
initi
diagnosi
relaps
intens
regimen
solid
tumour
high
risk
neuroblastoma
ewe
sarcoma
malign
brain
tumour
plu
myeloabl
condit
autolog
allogen
haemopoiet
stem
cell
transplant
hsct
also
associ
prolong
neutropenia
increas
risk
fn
cours
episod
fn
depend
upon
length
neutropenia
fever
patient
recov
within
h
commenc
broad
spectrum
antibiot
treatment
prolong
fn
greater
day
associ
fungal
infect
higher
associ
morbid
mortal
complex
treat
presenc
signific
comorbid
often
also
prolong
cours
diseas
children
document
infect
h
initi
blood
cultur
taken
afebril
h
clinic
stabl
whose
neutrophil
recov
either
step
oral
antibiot
antibiot
may
stop
altogeth
persist
neutropenia
neutrophil
count
persist
x
l
still
consid
stepdown
therapi
microbiolog
document
infect
clinic
well
afebril
diagnosi
fn
made
clinic
laboratori
ground
must
fever
low
anc
import
addit
import
histori
point
includ
type
durat
recent
chemotherapi
patient
chemotherapi
past
week
risk
fn
especi
true
myeloabl
chemotherapi
regimen
induct
treatment
acut
leukaemia
posthsct
thorough
physic
examin
crucial
patient
fn
repeat
least
daili
patient
unwel
focu
infect
often
found
lack
neutrophil
impair
immun
system
abil
produc
pu
erythema
localis
pain
therefor
regular
repeat
review
essenti
subtl
sign
miss
discount
irrelev
examin
includ
limit
vital
sign
temperatur
respiratori
rate
blood
pressur
heart
rate
assess
haemodynam
instabl
oral
tympan
temperatur
rectal
temperatur
measur
oncolog
patient
compromis
rectal
mucos
integr
induc
gramneg
bacteraemia
even
mild
trauma
skin
sign
cellul
abscess
impend
skin
integr
breakdown
includ
around
cvc
present
perineum
labial
skin
fold
examin
mouth
mucos
gingiv
examin
ear
nose
throat
sign
upper
respiratori
tract
infect
otiti
media
sinus
care
respiratori
examin
subtler
sign
infect
may
includ
elev
respiratori
rate
listen
heart
sound
abdomin
examin
includ
look
anal
fissur
check
new
hepatosplenomegali
blood
cultur
alway
taken
avail
lumen
cvc
repeat
blood
cultur
sampl
use
especi
case
growth
skin
commens
coagulaseneg
staphylococci
con
repeat
growth
organ
like
reflect
true
pathogen
oppos
contamin
addit
blood
test
includ
routin
blood
test
includ
full
blood
count
renal
liver
function
test
marker
inflamm
creactiv
protein
crp
erythrocyt
sediment
rate
esr
andor
procalcitonin
consid
may
fals
reassur
consid
blood
ga
venou
lactat
patient
unwel
assess
sepsi
empir
imag
asymptomat
patient
usual
indic
howev
follow
modal
consid
chest
swab
inflam
discharg
skin
mucou
membran
site
especi
purul
discharg
sent
microscopi
cultur
novel
diagnost
includ
polymeras
chain
reaction
pcr
blood
respiratori
secret
bodili
fluid
apart
urin
allow
faster
diagnosi
target
antimicrobi
therapi
may
shorter
durat
diarrhoea
prompt
consider
possibl
typhliti
neutropen
enterocol
possibl
clostridium
difficil
infect
especi
hsct
patient
gramneg
line
infect
diagnosi
fungal
infect
difficult
investig
modal
could
includ
abdomin
ultrasound
ct
chest
sinus
bronchoscopi
alveolar
lavag
identifi
hypha
biopsi
suspici
lesion
infecti
organ
identifi
fn
episod
bloodstream
infect
common
site
infect
includ
gastrointestin
tract
due
mucos
transloc
bacteria
upper
lower
respiratori
tract
urinari
tract
skin
soft
tissu
import
consid
noninfecti
caus
fever
particularli
children
young
peopl
respond
antimicrobi
treatment
possibl
caus
includ
drug
fever
induc
broad
spectrum
antibiot
chemotherapi
drug
tumour
lysi
especi
induct
chemotherapi
initi
stage
cancer
treatment
haemophagocyt
lymphohistiocytosi
hlh
blood
transfus
reaction
dysautonomia
central
nervou
system
diseas
involv
fn
caus
communityacquir
pathogen
opportunist
infect
must
also
consid
bacteria
common
caus
agent
viral
infect
also
common
children
fungal
infect
rememb
prolong
fn
also
import
rememb
possibl
noninfecti
caus
fever
patient
fail
improv
antimicrobi
therapi
gramposit
cocci
common
pathogen
found
fn
especi
skin
commens
secondari
increas
use
central
venou
line
prophylact
antibiot
coagulaseneg
staphylococci
especi
staphylococcu
epidermidi
staphylococcu
aureu
streptococc
speci
account
caus
organ
found
increas
use
fluoroquinolon
prophylaxi
associ
increas
rate
select
resist
due
select
intestin
pressur
gramneg
organ
less
common
may
lead
fulmin
clinic
cours
due
endotoxin
virul
factor
bacteri
pathogen
known
caus
seriou
infect
gramneg
organ
pseudomona
aeruginosa
among
gramposit
organ
staphylococcu
aureu
enterococcu
speci
especi
vancomycinresist
enterococcu
vre
streptococcu
viridan
common
gramneg
organ
includ
eschericia
coli
klebsiella
speci
pseudomona
speci
acinetobact
speci
enterobact
speci
polymicrobi
infect
increasingli
document
empir
antimicrobi
regimen
design
treat
gramposit
gramneg
organ
worryingli
increas
preval
resist
gramneg
may
increas
lead
reduc
efficaci
firstlin
empir
antibiot
communityacquir
viral
pathogen
common
gener
paediatr
also
often
seen
neutropen
children
respiratori
virus
commonli
includ
influenza
rsv
parainfluenza
rhinoviru
adenoviru
coronavirus
pathogen
progress
lower
respiratori
tract
infect
rapidli
immunocompet
host
length
sever
ill
usual
directli
proport
durat
neutropenia
fungal
infect
common
patient
profound
prolong
immunosuppress
children
treat
myeloabl
regimen
high
dose
steroid
prolong
neutropenia
prolong
cours
broadspectrum
antibiot
common
fungal
pathogen
candida
aspergillu
speci
candida
speci
transloc
across
damag
intestin
wall
mucos
candida
albican
common
candida
speci
candida
glabrata
candida
tropicali
common
patient
receiv
azol
prophylaxi
fluconazol
voriconazol
posaconazol
advent
antifung
prophylaxi
use
wide
mould
infect
often
aspergillu
speci
includ
aspergillu
fumigatu
also
fusarium
speci
becom
common
aspergillu
spore
often
inhal
environ
matur
upper
lower
respiratori
tract
cn
bone
skin
may
particularli
affect
aspergillu
individu
area
endem
bacteri
infecti
diseas
tuberculosi
fungal
infect
histoplasma
blastomyc
coccidioid
prone
new
infect
reactiv
latent
infect
receiv
chemotherapi
children
young
peopl
undergon
hsct
risk
type
infect
especi
fungal
infect
given
prolong
natur
neutropenia
also
risk
reactiv
certain
viral
infect
clinic
signific
viral
infect
usual
reactiv
latent
infect
seroposit
patient
virus
varicella
zoster
viru
vzv
herp
simplex
viru
hsv
epsteinebarr
viru
ebv
cytomegaloviru
cmv
case
antivir
prophylaxi
effect
avoid
sever
symptom
hsv
pose
risk
enceph
vzv
caus
persist
viremia
pulmonari
diseas
liver
failur
new
infect
reactiv
virus
caus
signific
morbid
mortal
hsct
fn
tradit
treat
inpati
set
howev
recent
model
risk
stratif
develop
identifi
oncolog
patient
may
benefit
outpati
treatment
earli
discharg
homebas
treatment
stabl
risk
stratif
attract
earli
discharg
associ
healthcar
save
decreas
rate
nosocomi
infect
low
risk
patient
patient
stratifi
high
low
risk
fn
base
upon
sever
factor
includ
gener
condit
patient
cancer
type
induct
infant
child
acut
myeloblast
leukaemia
aml
child
within
day
hsct
high
risk
intens
chemotherapi
expect
durat
neutropenia
neutrophil
count
less
x
l
seven
day
consid
high
risk
associ
comorbid
eg
renal
hepat
impair
increas
risk
complic
morbiditymort
localis
symptom
central
nervou
system
pulmonari
gastrointestin
especi
mucos
cvc
site
symptom
erythema
swell
increas
risk
modifi
alexand
rule
children
young
peopl
less
year
old
common
tool
use
uk
risk
assess
septic
complic
oncolog
patient
consid
lower
risk
septic
complic
unless
one
follow
condit
appli
treatment
aml
burkitt
lymphoma
induct
phase
treatment
progress
diseas
treatment
relaps
diseas
marrow
involv
present
follow
featur
hypotens
tachypnoea
hypoxiaddefin
satur
less
air
new
chang
cxr
alter
mental
statu
sever
mucos
vomit
abdomin
pain
focal
infect
clinic
reason
inpati
treatment
neutrophil
count
less
l
patient
deem
highrisk
treat
inpati
patient
consid
outpati
treatment
fn
must
increas
neutrophil
count
durat
neutropenia
expect
last
seven
day
children
must
stabl
renal
hepat
function
signific
comorbid
adequ
gastrointestin
absorpt
alreadi
receiv
cours
iv
therapi
h
famili
also
readili
contact
child
carer
easili
contact
live
within
close
proxim
medic
centr
case
deterior
avail
daili
review
receiv
fluoroquinolon
prophylaxi
previous
common
empir
regimen
outpati
manag
oral
ciprofloxacin
plu
amoxicillinclavulan
risk
stratif
may
effect
teenag
young
adult
age
group
teenag
young
adult
often
less
compliant
medic
treatment
often
receiv
higher
intens
chemotherapi
due
type
cancer
commonli
diagnos
research
ongo
better
method
stratifi
risk
adolesc
young
peopl
yet
prove
effect
treatment
base
upon
region
resist
pattern
patient
symptom
previou
cultur
result
sensit
infect
colonis
organ
first
line
treatment
fn
broad
spectrum
antibiot
ensur
coverag
gramposit
gramneg
organ
monotherapi
broad
spectrum
antibiot
shown
reduc
mortal
fewer
sideeffect
use
two
agent
betalactam
antibiot
eg
piperacillintazobactam
recommend
nice
first
line
monotherapi
unless
previou
microbiolog
result
indic
resist
organ
dosag
piperacillintazobactam
dose
accord
piperacillin
compon
everi
h
max
per
dose
case
anaphylaxi
penicillin
patient
cephalosporin
carbapenem
due
possibl
cross
reaction
patient
prescrib
broad
spectrum
agent
ciprofloxacin
plu
glycopeptid
vancomycin
teicoplanin
addit
glycopeptid
vancomycin
teicoplanin
advis
centr
high
rate
mrsa
colonis
cvc
remov
consid
patient
persist
bacteraemia
despit
h
appropri
iv
therapi
pneumoniacxr
chang
consid
addit
macrolid
antibiot
cover
atyp
organ
mycoplasma
pneumonia
especi
schoolag
children
legionella
fluoroquinolon
could
also
consid
possibl
pneumocysti
jirovecii
fungal
infect
aspergillu
speci
must
rememb
prolong
neutropenia
especi
unwel
patient
patient
vesicular
lesion
unwel
viral
symptom
commenc
aciclovir
betalactam
carbapenem
provid
good
anaerob
organ
cover
patient
suspect
intraabdomin
pelvic
sepsi
agent
iv
metronidazol
commenc
addit
glycopeptid
better
cover
skin
commens
organ
may
benefici
patient
microorgan
confirm
infect
antimicrobi
therapi
tailor
particular
infect
antibiot
sensit
durat
day
usual
appropri
depend
upon
organ
longer
cours
gramneg
organ
neutrophil
count
antimicrobi
often
continu
neutrophil
count
consist
increas
patient
new
clinic
instabl
worsen
symptom
urgent
reassess
consider
reinvestig
escal
treatment
glycopeptid
aminoglycosid
recommend
first
line
therapi
fn
side
effect
risk
promot
emerg
resist
vancomycinresist
enterococcu
howev
ad
appropri
indic
suspect
confirm
mrsa
glycopeptid
aminoglycosid
gentamicin
amikacin
ad
treatment
regimen
unwel
septic
patient
cover
possibl
resist
gramneg
organ
coloni
stimul
factor
gcsf
routin
use
uk
consid
sever
prolong
neutropenia
without
anticip
bone
marrow
recoveri
signific
sepsi
patient
febril
h
antimicrobi
therapi
especi
neg
blood
cultur
investig
fungal
infect
commenc
antifung
treatment
common
first
line
antifung
drug
liposom
amphotericin
b
option
includ
echinocandin
eg
micafungin
triazol
eg
voriconazol
patient
receiv
antifung
prophylaxi
prior
episod
fn
antifung
treatment
differ
class
usual
chosen
treatment
liposom
amphotericin
usual
chosen
renal
dysfunct
prognosi
depend
upon
sever
factor
includ
clinic
state
time
present
requir
intens
care
intub
inotrop
support
usual
wors
outcom
organ
involv
gramneg
fungal
organ
often
confer
wors
outcom
underli
malign
expect
prolong
period
neutropenia
vulner
fungal
infect
complic
result
infect
mortal
report
high
hospit
patient
gramposit
infect
document
gramneg
infect
fungal
infect
higher
still
howev
patient
recov
fn
episod
without
ongo
problem
prophylact
antimicrobi
treatment
involv
administr
treatment
dose
antibacteri
agent
often
fluoroquinolon
certain
highrisk
patient
aml
syndromeassoci
leukaemia
consider
antifung
prophylaxi
triazol
itraconazol
line
care
bundl
involv
standard
regim
around
line
insert
access
shown
reduc
bacteri
bloodstream
infect
gingiv
complic
oral
mucos
avoid
good
mouth
care
prevent
emerg
multidrug
resist
strain
especi
gramneg
organ
achiev
good
prevent
strategi
good
antimicrobi
stewardship
c
febril
neutropenia
common
condit
paediatr
oncolog
set
especi
induct
phase
acut
leukaemia
preengraft
phase
allogen
hsct
c
prompt
recognit
diagnosi
requir
prevent
sever
complic
includ
death
c
empir
therapi
broad
spectrum
antibiot
initi
quickli
min
door
administr
antibiot
c
first
line
treatment
usual
antipseudomon
beta
lactam
antibiot
piperacillintazobactam
c
risk
stratif
use
guid
manag
use
centr
c
prognosi
depend
upon
sever
factor
includ
organ
system
involv
sever
diseas
emerg
resist
gramneg
organ
led
increas
mortal
